Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $117.00

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has received a consensus rating of “Buy” from the twenty-two research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $117.00.

Several brokerages have recently weighed in on KYMR. Royal Bank Of Canada increased their price objective on shares of Kymera Therapeutics from $70.00 to $103.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Stephens upped their price target on shares of Kymera Therapeutics from $65.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, December 11th. Morgan Stanley lifted their price target on shares of Kymera Therapeutics from $73.00 to $127.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. BTIG Research reissued a “buy” rating and set a $138.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday. Finally, UBS Group upgraded Kymera Therapeutics to a “strong-buy” rating in a report on Thursday, December 4th.

Kymera Therapeutics Stock Up 0.6%

KYMR stock opened at $77.70 on Monday. The stock has a market capitalization of $5.59 billion, a price-to-earnings ratio of -21.64 and a beta of 2.21. Kymera Therapeutics has a 52-week low of $19.44 and a 52-week high of $103.00. The stock’s fifty day simple moving average is $76.25 and its 200-day simple moving average is $60.47.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.19). Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.The business had revenue of $2.76 million for the quarter, compared to analysts’ expectations of $23.15 million. As a group, analysts anticipate that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Activity at Kymera Therapeutics

In other news, Director Bruce Booth sold 678 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $91.04, for a total value of $61,725.12. Following the transaction, the director directly owned 685,393 shares in the company, valued at $62,398,178.72. This trade represents a 0.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bros. Advisors Lp Baker bought 2,005,813 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were purchased at an average price of $86.00 per share, with a total value of $172,499,918.00. Following the acquisition, the director directly owned 7,955,916 shares in the company, valued at approximately $684,208,776. This trade represents a 33.71% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold a total of 420,895 shares of company stock valued at $37,778,351 over the last three months. Insiders own 16.01% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors have recently bought and sold shares of the business. US Bancorp DE increased its holdings in Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after buying an additional 166 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Kymera Therapeutics by 9.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock worth $156,000 after acquiring an additional 248 shares in the last quarter. Larson Financial Group LLC grew its position in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after acquiring an additional 349 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after acquiring an additional 540 shares during the last quarter. Finally, Harbor Capital Advisors Inc. raised its position in shares of Kymera Therapeutics by 2.2% during the 4th quarter. Harbor Capital Advisors Inc. now owns 30,573 shares of the company’s stock valued at $2,379,000 after acquiring an additional 645 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.